HoldsUp

Daniel Amen

Dr. Daniel Amen is a researcher and author working in the field of neuroimaging and psychiatric health. His published research focuses primarily on using brain single-photon emission computed tomography (SPECT) imaging to assess regional cerebral blood flow and neural connectivity. His work investigates functional brain imaging biomarkers across psychiatric and neurological conditions, including major depressive disorder, schizophrenia, ADHD, cognitive disorders, and the effects of adverse childhood experiences.

60 claims checked on air: 7 context 2 contradicted 6 overstated 36 supported 9 unverified

What they said on air - contradicted

8 citing their own research

0:56:00contradictedmoderateRecognize Influences on the Brain - with Dr. Daniel Amen | T

Low blood flow is the number one brain imaging predictor of Alzheimer's disease.

"Blood flow—low blood flow is the number one brain imaging predictor of Alzheimer's disease." (said at 0:56:00)

Low cerebral blood flow (hypoperfusion, typically assessed via SPECT or arterial spin labeling MRI) is not the leading or "number one" neuroimaging predictor of Alzheimer's disease. In clinical diagnostic frameworks and comparative imaging studies, pathological hallmark imaging (amyloid-beta PET and tau PET), fluorodeoxyglucose (FDG) PET, and structural MRI (such as medial temporal lobe and hippocampal volumetry) are the primary, most accurate imaging biomarkers for Alzheimer's disease. While characteristic patterns of hypoperfusion (particularly in the posterior cingulate and temporoparietal cortices) are observed in Alzheimer's disease and can assist in differential diagnosis or prognostication of mild cognitive impairment, systematic reviews and comparative studies demonstrate that FDG-PET and specific amyloid/tau imaging biomarkers consistently demonstrate higher diagnostic accuracy and predictive power than perfusion imaging.

0:08:25contradictedhighProven Strategies to Prevent Disease - with Dr. Daniel Amen

Low cerebral blood flow, particularly in the hippocampus, parietal lobes, and posterior cingulate gyrus, is the primary brain imaging predictor of Alzheimer's disease.

"The number one brain imaging predictor of Alzheimer's disease is low blood flow, especially in the hippocampus and in the back half of your brain, the parietal lobes, and an area called the posterior cingulate gyrus." (said at 0:08:25)

While hypoperfusion and hypometabolism in the posterior cingulate cortex, parietal lobes, and hippocampus are well-recognized neurodegenerative patterns in Alzheimer's disease (AD), low cerebral blood flow is not the primary or "number one" neuroimaging predictor of AD. Under the established National Institute on Aging and Alzheimer's Association (NIA-AA) diagnostic and research frameworks, the primary Core-1 and Core-2 diagnostic imaging biomarkers for Alzheimer's disease are amyloid-beta PET and tau PET. Functional imaging measures such as regional perfusion or FDG-PET metabolism reflect downstream neurodegeneration ('N') or vascular changes ('V') rather than the primary disease-defining biomarkers.

Fact-checked episodes

Publications